Introduction
Genetically modified replication-selective human adenoviruses (Ad) like ONYX-015 are currently undergoing testing as anticancer agents in human clinical trials. [1] [2] [3] [4] [5] This treatment takes advantage of the lytic nature of the productive viral infection to eradicate the tumor mass. Creating an Armed Therapeutic Viruses platform, where the lytic property of the viral infection is coupled with virus-mediated delivery of therapeutic transgenes, enhances the potential of the virus-based therapy to deal with the complexity of the human tumor. 6 The Ad5 early region 3 transcription unit (E3) is an ideal site for developing the transgene delivery capacity of the replicating virus 7 since the E3 region is non-essential for viral replication in vitro. [8] [9] [10] In this article, we describe the continuing development of such a system from the replicating Ad, where the endogenous E3 region gene expression control signals (promoter, splicing, polyadenylation signals; reviewed in Ref. 11 ) are used to express the therapeutic transgene from a substituted E3 gene or region. In this study, we look at transgene expression from the E3-ADP (adenovirus death protein, E3-11.6 K) region.
The ADP gene replacement represents a special case in the E3 region. Unlike other E3 genes, ADP is expressed almost exclusively during the late phase of the viral infecCorrespondence: T Hermiston, tion. 12 While nearly all other E3 genes described have immunomodulatory functions, 13 ADP is responsible for the efficient lysis and release of progeny virus from the infected cell. 14, 15 Cells infected with an ADP-deleted Ad live longer and maintain protein synthesis over the extended course of the viral infection. 14, 15 Consequently, an ADP-deleted virally infected cell should serve as a 'factory' for therapeutic protein synthesis, using both viral replication-derived genomic amplification and the extended infected cell viability and protein synthesis to produce more of the beneficial therapeutic transgene(s).
In this study, the ADP gene was replaced with the bacterial pro-drug converting enzyme cytosine deaminse (CD) or the cytokine, tumor necrosis factor (TNF␣) (see Figure 1 ) in an Ads background. We show that the transgene expression pattern mimics the normal ADP expression pattern, maintaining the predominate late gene expression pattern and dependence on the occurrence of viral DNA replication for maximum expression. The ADP substituted recombinant Ads display a significant delay in the lysis of the infected cell and prolonged protein synthesis over wild-type Ad5. Importantly, these transgene insertions did not alter the expression of adjacent E3 genes.
Results

Transgene expression from Onyx-305 and -320
One of the predictions of the gene delivery model is that the expression of the substituted transgene should mimic the pattern of the substituted endogeneous adenoviral gene, in this instance, ADP. To test this, A549 cells were infected with recombinant viruses ONYX-305 (CD), ONYX-320 (mTNF␣) or Ad 5 (parent virus) and transgene expression and endogenous ADP levels were examined over the course of the viral infections by Western blot analysis. ADP expression from Ad5 was detected by 24 h p.i. (Figure 2a ) although minor levels of ADP have been previously described as occurring as early as 13 p.i. 12 Minor levels of CD expression from ONYX-305 were detected by 12 h p.i. (Figure 2b ), consistent with the previously published data, 12 while mTNF␣ expression from ONYX-320-infected cells was detected at 24 p.i. (Figure 2c ).
To analyze further whether transgene expression is mimicking the ADP expression pattern (ie expressed predominately during the late phase of the viral life cycle), viral infections were performed in the presence of araC. The addition of this inhibitor of DNA replication should (Figure 3a and d) . At later times after infection, levels of gp19 K expression did wane in both viruses, consistent with previous observations 7 and suggesting that maximal gp19 K expression is dependent on viral DNA synthesis. Synthesis of pVIII, a structural protein made from the late transcription unit L4, was blocked by the presence of araC (Figure 3b and e) . ADP protein expression, like pVIII, was inhibited by the presence of araC (Figure 3c ), as was the substituted transgene, mTNF ( Figure 3f ). Similar results were seen for CD expression from ONYX-305, although minor levels could be detected if the gel was overexposed (data not shown), suggesting some low level of expression at early times after infection. Why CD and not TNF␣ is detected early in infection and in the presence of araC is not clear and may be due to antibody sensitivity. It is clear, however, that placing the transgenes CD and mTNF␣ in the ADP position limits expression almost exclusively to the late phase of infection, confirming the premise that the expression of the substituted gene mirrors the replaced ADP gene.
Expression of proteins adjacent to the ADP transgene insertion is maintained in ONYX-305 and -320
The E3 transcription level has various cis signals that control the abundance of the various E3 mRNAs over the course of the viral infection (reviewed in Ref. 11) . One of these signals is encoded within the ADP gene and its loss is responsible for drastically altered levels of mRNA that should result in reduced gp19 K protein levels and increased RID␤ and 14.7 K protein levels. However, some mutants that do not synthesize ADP do not have this phenotype. 16 How transgene insertions in the ADP region would affect the expression of surrounding genes in the complex E3 transcription unit was investigated. A549 cells were infected with Ad5, ONYX-320 or ONYX-305 and the expression of the E3 genes which surround the ADP gene (gp19 K, RID␤ and 14.7 K) was examined by Western blot analysis. The timing and levels of expression of the gp19 K, RID␤ and 14.7 K proteins were similar to that seen in the wild-type Ad 5 infection (Figure 4 ). It should be noted, however, that there appears to be a processing difference in the RID␤ protein expressed from both ONYX-320 ( Figure 4b ) and ONYX-305 (data not shown), where the lower protein bands do not appear. Interestingly, this same phenomenon occurs during Ad5 infection in the presence of araC, or in a viral mutant that has a deletion in the y leader sequences such that ADP is not synthesized. 7 The reason for this processing difference is unclear but appears to be directly or indirectly dependent on the expression of the ADP gene.
Quantification of mTNF expression
To quantify levels of mTNF␣ transgene expression from the ADP region, medium from ONYX-320-infected cells
Figure 3 Expression from the ADP region is dependent on viral DNA replication. A549 cells infected with Ad5 or ONYX-320 at an MOI of 10 in the presence or absence of araC an inhibitor of DNA replication. Cell lysates created at the indicated times p.i. were probed with antibody to E3-gp19 K (panels a and d), pVIII (panels b and e), ADP (panel c) or mTNF (panel f).
Figure 4 Expression of surrounding E3 genes in ONYX-320 infected cells. A549 cells were infected with Ad5 or ONYX-320 at an MOI of 10 and harvested at the indicated times p.i. Western blots were probed with antibody to the E3 proteins (a) gp19 K, (b) RID␤ or (c) 14.7 K.
was analyzed at specific times over the course of the viral infection. A549 cells were infected at an MOI of 10 and the medium was changed 1 h before the indicated timepoints. This created 1-h incubation periods to determine active de novo, not cumulative, expression of the mTNF␣. This assay was performed in quadruplicate to account for plate-to-plate or infection variability. As shown in Figure  5 , mTNF␣ production peaked at 36 h p.i., with levels as high as 63 ng mTNF␣/million cells/h. As further confirmation that mTNF␣ was expressed primarily as a late gene, araC was added and mTNF␣ production was measured by ELISA. In this case, the levels produced were low and similar to the early time-points without araC. This is consistent with the low levels of ADP and CD detected during the early phase of the viral infection. This may indicate sensitivity differences between the TNF␣ and CD antibodies and that TNF␣ is expressed to very minor levels, like ADP and CD at early times postinfection.
Virally derived mTNF and CD are functional
The human Ad alters the infected cell to maximize the production of progeny virus. In this process, normal cellular pathways are altered. To ensure that these virally induced modifications did not alter the functions of the virally synthesized mTNF␣ and CD proteins, activity assays were conducted. For mTNF␣, sensitive L929 cells were exposed to conditioned medium collected from ONYX-320 infected cells at 36 h p.i. The amount of mTNF␣ in these samples was measured by ELISA, seri- ally diluted to the indicated concentrations (Figure 6a) , and added to L929 cells in the presence of actinomycin D. After 24 h viability was assayed by crystal violet staining. The same experiment was performed in parallel using recombinant mTNF␣ (rmTNF␣) diluted to the same concentrations. Using the conditioned medium from ONYX-320-infected cells, Figure 6a shows that all the cells were killed at concentrations down to 0.05-0.5 ng/ml and was in agreement with the results obtained with rmTNF␣. Therefore, the mTNF␣ produced by ONYX-320 behaves like rmTNF␣, confirming that it is biologically active.
CD protein from ONYX-305-infected cells was tested for enzymatic activity by examining its ability to convert cytosine to uracil. Using an in vitro assay, the conversion of labeled cytosine to uracil was detected by 24 h p.i., confirming that the virally derived CD was enzymatically active (Figure 6b ). To confirm that CD expression occurs in the late phase of the virus infection, araC was added to the infected cells and CD activity was again assayed. As seen previously, CD activity did occur with late expression kinetics, with trace amounts detected early (Figure 6b) . Thus, the CD and TNF␣ proteins generated by the recombinant viruses were active and exhibited ADP-like late gene expression kinetics.
CPE analysis of ONYX-305 and ONYX-320
The loss of ADP can result in a demonstrable alteration in virally induced CPE. 14, 15 To test whether the substitution of transgenes for the ADP gene further altered the viral life cycle, recombinant adenoviruses ONYX-305, ONYX-320, ONYX-300 (ADP deleted, no transgene insertion) (see Figure 1 ) and the wild-type Ad5 were analyzed for their ability to induce cytopathic effect (CPE) in A549 cells. Cells infected with the ADP-deleted virus ONYX-300 round up but remain attached and intact Gene Therapy when compared with Ad5-infected cells (Figure 7 ). The transgene expressing viruses ONYX-305 and -320, however, show a significant delay in time to 100% CPE relative to both wild-type virus Ad5 and ONYX-300 ( Figure  7) ; not only did the cells remain attached but there was a delay in the time to cell rounding up. These results suggest that the deletion of ADP does have an effect on the appearance of CPE and implies that the transgene substitution for ADP further attenuates the appearance of CPE as compared with an ADP deletion mutant such as ONYX-300.
The CPE noted with ONYX-305 and -320 infected cells was attenuated relative to the wild-type Ad5. To test whether the extended cell viability was reflected in a prolonged window of protein translation, A549 cells were infected with Ad5, ONYX-305 and -320 and radiolabeled for 2 h before the indicated time-points and then harvested and subjected to SDS-PAGE analysis. Active translation, indicated by incorporation of radiolabel into newly synthesized proteins, was interpreted as a measure of cell viability. As seen in Figure 8 , protein synthesis was extended in the ADP-substituted viruses ONYX-305 and -320 by as much as 24 h compared with Ad5. This is in agreement with previous reports on ADP mutant viruses.
14,15 Interestingly, ONYX-320 appears to incorporate label further into the infection than ONYX-305 ( Figure 8 ).
Viral yield
To assay whether prolonged cellular metabolism associated with ADP-deleted recombinant Ads could result in larger viral progeny yield per cell, A549 cells were infected with ONYX-300, -305, -320, or Ad5 and the cells and culture medium were harvested separately at 24, 48, 72, and 96 h p.i. and assayed for the production of infectious virus. Since ADP is responsible for the efficient lysis of the cell, loss of ADP in ONYX-300, -305, and -320, as predicted, was reflected by a reduction of virus released into the culture medium when compared with Ad5 ( Figure 9 ). The extended viability of the infected cell did result in a slight increase in infectious progeny virus produced in the infected cell (compare Ad5 with the ADPdeleted ONYX-300 and -320, Figure 9 ) with the exception of ONYX-305. The transgene expressing viruses ONYX-305 and -320 display striking differences in virus production, suggesting potential transgene effects. Therefore, while it does appear that there is an increase in viral progeny per cell with the loss of ADP, these results suggest that the transgene choice can make detectable differences although the mechanism(s) remain unclear.
Discussion
In this article, we have extended our studies targeted at developing a novel system for delivering transgenes from a replicating virus. 7, 17 In this system, E3 genes, in combination or individually, are selectively removed and substituted with therapeutic transgenes. This is done while the endogenous adenoviral promoters, polyadenylation sites, and splicing sites are maintained. Incorporating transgenes into the E3 region in this fashion should create a system where the initiation and level of transgene expression could be predicted based on the expression pattern of the substituted endogenous adenoviral E3 gene(s). This has been demonstrated for the E3 6.7 K/gp 19 K and E3B regions. 7, 17 In this paper, gene delivery from the E3 ADP gene region was examined.
The ADP protein is necessary for efficient release of viral progeny from the infected cell. Its deletion results in delayed lysis and, concurrently, extended protein synthesis. Our prediction was that by replacing the ADP Gene Therapy gene with a therapeutic transgene, this gene would not only be expressed almost exclusively at late times after infection but it would also result in an infected cell with prolonged transgene expression as a result of the extended life cycle of the infected cell. Selective removal and replacement of ADP with either the E. coli CD or the mTNF␣ genes confirmed many of these predictions. In keeping with the system design, transgene expression mirrored the expression of the ADP gene, recognizing maximum transgene expression during late times in the viral infection (Figures 2 and 3) . Transgene insertion and expression had minimal effects on the expression of the E3 genes gp19 K, RID␤ and 14.7 K which surround the ADP gene (Figure 4 for ONYX-320; data not shown for -305). These recombinant viruses displayed a predictable delay in CPE relative to both the Ad5 and ONYX-300 (ADP-) viral infections ( Figure 7 ). The enhanced cell viability seen with these virally infected cells is translated into prolonged 14, 15 and (Figure 8 ) and robust ( Figure 5 ) expression of the therapeutic transgene. The mTNF␣ generated from the ONYX-320 infected cells was properly processed from the plasma membrane-bound precursor to the mature secreted form (Figures 2c and 3f ) and both CD and mTNF␣ are functional by standard assays (Figure 6 ). The viral progeny of ONYX-300, -305 and -320, as predicted, stayed more cell-associated compared with Ad5 ( Figure 9 ). Additionally, we predicted the production time of viral progeny would be lengthened and more viral particles might be generated from the infected cell. While differences were noted in the amount of infectious virus produced from a single infected cell from the transgene-expressing viruses ONYX-305 and -320, a generalized increase in viral progeny produced per cell was noted. Interestingly, ONYX-320 produced much higher levels of progeny virus per cell than ONYX-305, suggest-ing potential transgene effects. Since these transgenes differ in their size and function, it is not clear if these or other factors are responsible for these differences. Consistent with this observation, protein synthesis in ONYX-305 did not extend to the same time-point seen with ONYX-320, indicating a potential transgene effect (Figure 8 ).
Recombinant Ads expressing therapeutic genes from the ADP region of the virus have several properties that should be exploitable in the clinical setting. Transgene insertions into the ADP region offer prolonged gene expression as reflected by their extended cell metabolism over Ad5-infected cells 14, 15 (Figure 8 ). As discussed previously, this is the result of inefficient lysis of the infected cell due to loss of the ADP gene and should allow the infected cell to operate as a 'factory', expressing high levels of the therapeutic transgene. Since four of the seven known E3 proteins have roles in immunoregulation, and these genes are retained and expressed from these viruses, these infected cells may benefit from the immune evasion offered by these E3 proteins in vivo (reviewed in Ref. 13) .
Therapeutic transgenes encoding diffusable proteins capable of acting at a distance from the infected cell or agents that are dependent on prolonged gene expression may benefit from insertion into the ADP region of the replicating Ad. We have chosen two therapeutic genes that might benefit from this type of expression, TNF␣ and CD. Converting the non-toxic prodrug 5-FC to the toxic chemotherapeutic 5-FU, CD functions in a stoichiometric fashion, and stands to benefit from the extended levels of expression. Toxic 5-FU is a diffusable anabolite, responsible for the bystander effects which extend the oncolytic potential of the virus beyond the virusmediated lysis of the infected cell. Since viral DNA replication should occur before the majority of the pro-drug converting enzyme is expressed, this system may allow the virus to avoid the toxic effects of the 5-FU in the initial infection. Subsequent dosing of 5-FC will require careful consideration to maximize continued viral replication and spread.
TNF has been intensely studied as a potential cancer therapy since initial observations of in vitro tumor cell line toxicity 18 and in vivo solid tumor hemorragic necrosis. 19 Antitumoral activities of TNF␣ include chemoand radio-sensitization [20] [21] [22] [23] and anti-angiogeneic [24] [25] [26] activities and these may benefit from the prolonged expression associated with the ADP− adenovirus infection. Unfortunately, dose-limiting systemic toxicities have restricted the use of TNF in the clinical setting. [27] [28] [29] [30] Administration of TNF via a tumor-specific vehicle such as ONYX-015 could serve to reduce the systemic cytotoxic events by concentrating the inherent antitumoral properties of the cytokine to the local tumor environment.
A potential drawback to TNF␣ expression from the replicating virus is that TNF␣ has antiviral activity. [31] [32] [33] [34] However, the E1B-19 K protein and the E3 RID␣, RID␤ and 14.7 K proteins inhibit TNF mediated lysis 32, 35 and are retained in the ADP-deleted transgene-expressing viruses (Figure 4 , data not shown). These proteins should serve to protect the infected cell from the deleterious effects of TNF. An additional advantage to retaining these proteins is that they are multi-functional, acting at various levels to enhance the survival of the virus infection (reviewed in Ref. 35 ).
An additional advantage to placing genes in the ADP region is that maximal transgene expression is linked to viral replication. This is important since it may be necessary to introduce viruses intravenously to eradicate distant tumor metastasis. If the selectivity of the virus is engineered to events preceding viral DNA replication (attachment, penetration, early gene expression), transgene expression from the ADP region should be minimal in normal cells and maximal in the target cancer cells where replication can occur. Previous examples of gene delivery from the replication-selective Ad used the perpetually active HCMV enhancer-promoter to drive transgene expression. 36, 37 In these viruses, the expression of the therapeutic transgene could occur in any infected cell. Linking transgene expression to viral DNA replication and the genetically engineered selectivity of the virus limits the potential for deleterious events due to inappropriate transgene expression.
In this study, we have extended our investigation into the Ad E3 region as a means of delivering transgenes from a replicating adenovirus, taking advantage of its complex regulation to deliver genes in a predictable fashion using the endogenous gene expression machinery. We show that transgene substitutions into the ADP region result in the exogenous protein being expressed during the late phase of infection to high levels that are extended by the prolonged life of the virally infected cell due to the loss of ADP. By inserting a transgene and maintaining expression of the remaining immunomodulating E3 genes, this system should enhance the immune evasion potential of the virus. Maintaining the expression of the remaining E3 genes keeps open the possibility that additional transgene substitutions could also be made for the other E3 genes, giving way to the delivery of multiple therapeutic genes from a single virus. In complex targets such as tumors, this multi-directed attack may be essential to engineering clinical benefit. Efforts to create such viruses are currently underway.
Materials and methods
Cells and viruses
The A549, 293, KB spinner cell lines and wild-type Ad5 virus were acquired and propagated as described previously.
7,17
Shuttle vector construction The plasmid pSN was described previously. 7 Briefly, it contains the Ad5 genomic sequences from the SpeI site (27 802) to the NdeI site (31 089) inserted into the vector pGEM5Zf+ (Promega, Madison, WI, USA) between the SpeI and NdeI sites (all numbering is derived from the Ad5 genome sequence, accession No. M73 260). To remove the ADP gene, BstBI and StuI restriction endonuclease sites were generated at nucleotides 29 483 and 29 720 in the viral genome, respectively. Mutagenesis was performed by PCR 38 using mutant primers 5ЈCCCAAA-CAATGAAGGCCTCCATAGATTGG and 5ЈGCGACCCA CCCTTTCGAACAGAGATGACCAAC. This resulted in the plasmid pSN-BS, the basic vector for transgene insertions into the ADP region.
Insertion of the CD gene or the TNF gene into pSN-BS
The E. coli CD gene was isolated from the plasmid pCD2 (ATCC, Bethesda, MD, USA; No. 40999) and modified as previously described. 7 The restriction enzyme sites BstBI and StuI were added 5Ј and 3Ј of the CD gene, respectively, by PCR amplification. Both the pSN-BS vector and the transgene-containing PCR product were digested with BstBI and StuI (NEB) and the gel-purified (Qiagen, Santa Clara, CA, USA) fragments were ligated using T4 DNA ligase (Roche, Indianapolis, IN, USA). Transformants were screened by restriction enzyme digestion and confirmed by sequencing. The resulting ADP-substituted CD-containing plasmid was called pSN-CDBstStu.
The murine TNF␣ (mTNF) gene was isolated from the plasmid pMuTNF (ATCC No. 63 169) by PCR using a Pfu polymerase (Stratagene, La Jolla, CA, USA)-mediated PCR reaction. As a result of the PCR reaction, a BstBIcompatible ClaI restriction endonuclease site was generated at the 5Ј end and a StuI site at the 3Ј end. BstBI and StuI restriction enzyme-digested vector pSN-BS and the ClaI and StuI-digested TNF-amplified PCR product were gel-purified and ligated together. The resulting plasmid, pSN-mTNFBstStu, was identified by restriction enzyme digestion and confirmed by sequencing; it contains the entire gene for mTNF including the pro-sequence.
An ADP-deleted virus control was generated by T4 DNA polymerase (Roche) fill-in of the BstBI and StuI restriction enzyme-digested plasmid pSN-BS and subsequent relegation. This plasmid, which also contains a BstBI site at the MunI site (nt 29 355) via linker addition, was called pSN-dlADP and was used to construct the virus ONYX-300.
Virus construction
All conditions described below are for a 6 cm plate with all transfections performed in duplicate as previously described. 7 Briefly, 0.5 g of Ad5 TP-DNA and 10 g of the plasmids pSN-dlADP, pSN-mTNFBstStu, and pSNCDBstStu were digested with the restriction endonuclease EcoRI. Digested plasmids were run on a 1% agarose gel and the transgene-containing EcoRI fragment was isolated and ligated to 0.5 g of EcoRI-digested TP-DNA, using 5 units of T4DNA Ligase (Roche), overnight at 16°C and used to transfect A549 cells as previously described. 7 Viral screening, propagation, and large-scale production were performed as previously described. 7 Enzymatic assay for CD activity The assay for CD activity from infected cells was as previously described. 7 Briefly, cell lysates were prepared as described for Western blot analysis with 1 g of total protein used in each reaction, along with 5 l of substrate, 5 mm [2-14 C]-cytosine (Movarek Biochemicals, Brea, CA, USA) in a 10 l reaction. The reaction was incubated for 20 min at 37°C, and then stopped with equal volumes of cold 4 mm cytosine/uracil. Seven l of the reaction mixture was loaded on to a TLC plate (Mallinckrodt Baker, Phillipsburg, NJ, USA; Silica gel), resolved with 1-butanol:H 2 O (86: 14) , and then exposed to film overnight.
Western blot analysis
Infections and sample preparation were performed as previously described. 7 Briefly, A549 cells were infected at an MOI (multiplicity of infection) of 10 and then the cells were harvested at the indicated times post infection (p.i.).
Gene Therapy
Twenty g of total protein for each sample was run on a 4-20% PAGE gel and then transferred to PVDF membrane (Amersham, Piscataway, NJ, USA). The polyclonal rabbit antibodies to the adenoviral proteins gp19 K, ADP, RID␤, 14.7 K, pVIII and transgenes CD and mTNF were acquired and used as previously described. 7 For Western blot analysis of infected cell culture medium, the medium was changed 1 h before each indicated time-point and 5 ml of fresh DME/2% FBS was placed on to cells. After 1 h, this medium was removed and aliquoted for analysis by Western blot and for quantification by ELISA. For these Westerns, 25 l of this conditioned medium per lane was run on a gel and processed as above. To define late protein expression, araC (1-␤-d-arabinofuranosylcytosine: Sigma Chemical, St Louis, MO, USA) was added to the culture medium of the viral infections to a final concentration of 20 g/ml. This agent inhibits DNA replication, restricting the infection to the early phase of the viral infection. The infections and the analysis were carried out as described above.
Quantitation of mTNF by ELISA
To quantify the amount of mTNF secreted into the culture medium, the Cytoscreen mTNF kit (BioSource International, Camarillo, CA, USA; No. KMC3012) was used as previously described.
7
L929 cell killing assay Confluent L929 cells in 24-well plates were exposed to various dilutions of either recombinant murine TNF (rmTNF; Biosource International) or 36 h p.i. conditioned culture medium from A549 cells infected with either Ad5-or ONYX-320. The amount of mTNF in the conditioned medium was quantified by ELISA and both mTNF and rmTNF were diluted to 50 ng/ml in DME/10% FBS/4 g/ml actinomycin D (Sigma, St Louis, MO, USA). Ten-fold dilutions were made from 50 ng/ml to 0.005 ng/ml. Conditioned culture medium from cells infected with Ad5 served as a control. One half ml of each of these samples was added to the confluent L929 cells and each treatment was done in triplicate. This was allowed to incubate on the cells for 24 h. The cells were fixed with 95% ethanol and then exposed to 0.05% crystal violet in methanol to visualize the cell monolayer loss as a measure of mTNF-induced cytotoxicity. This was allowed to stain for 10 min, removed, and cell monolayers were rinsed with water and air-dried prior to scanning.
ELISA to determine titers for burst assay A549 cells were infected at an MOI of 10 and at 24 h intervals, the cells and the medium were collected separately. Cells were frozen and thawed three times to release intracellular viral particles and the virus yield was determined by an ELISA developed to determine viral titers. Briefly, 293 cells were seeded into a 96-well plate at a density of 5 × 10 4 cells per well and allowed to attach for 1 h before addition of serially diluted viruses. Forty eight hours p.i., cells were rinsed with PBS and fixed with 95% ethanol/5% acetic acid for 15 min at −20°C. After washing with PBS, 200 l of Superblock (Pierce, Rockford, IL, USA) was added to each well and incubated at room temperature for 1 h before removal and addition of 100 l of rabbit anti-adenovirus antibody (Access BioMed, La Jolla, CA, USA; 1:1000 in Tris-buffered saline containing 1.35% normal goat serum) to each well. After 1 h at room temperature with shaking, the plates were washed three times with TBST (Pierce; TBS with 0.1% Tween 20) and 100 l of goat anti-rabbit AP conjugated antibody (Pierce; diluted 1:1000 in TBST) was added to each well and shaken for 1 h. The wells were washed with TBST three times. The substrate solution PNPP (p-nitrophenyl phosphate; Pierce) in diethanolamine was added (100 l per well), shaken for 7 to 10 min (until color developed), and then stopped by the addition of 100 l of 2 n NaOH. After shaking for 5 min, the wells were analyzed using SoftMax program with a plate reader at an OD of 405 nm and the virus titer was determined on a standard curve generated by a virus standard.
Total protein labeling
Mock and virally infected cells were radiolabeled with 50 Ci of 35 S (EasyTag Express; NEN, Wilmington, DE, USA) in 1 ml of methionine-and cysteine-free medium (Life Technologies, Rockville, MD, USA) plus 2% dialyzed FBS (Irvine Scientific, Santa Ana, CA, USA) for 2 h before each time-point taken. Cells were collected and treated as described for Western blot analysis. Two l of each sample (1% of total volume) was loaded on to a 14% SDS-PAGE gels. Gels were fixed for 30 min in 10% acetic acid/30% methanol, treated with Enlighten (NEN) for 30 min, dried, and exposed to film overnight.
